Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04132830 · ClinicalTrials.gov registry record
HIV Exposure in Utero and Metabolic Disease Risk in HIV-Negative Young Adults
A clinical trial, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- 174
- Enrollment target
NCT04132830: Completed study, sponsored by Massachusetts General Hospital.
NCT04132830 is a clinical trial that has completed, run by Massachusetts General Hospital. The registered enrollment target is 174 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04132830 has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- 174 participants
- Enrollment target
Study Summary
Globally, over 1 million babies are born to mothers with HIV each year. With the advent of prenatal antiretroviral therapy, up to 98% of these individuals may be HIV-exposed uninfected (HEU). A growing literature suggests that in utero HIV exposure - even in the absence of subsequent infection - may be associated with adverse health outcomes in infancy and childhood. However, there is little information about the long-term health implications of in utero HIV exposure later in life, such as into adulthood. In this study, for the first time, we seek to prospectively evaluate metabolic and immune indices among HEU young adults as compared to well-matched HIV-unexposed uninfected controls. This study serves as a necessary first step toward optimizing clinical care for this expanding and aging HEU population, including the implementation of novel screening and prevention strategies.
Interventions
- OTHER In Utero HIV Exposure
- OTHER No In Utero HIV Exposure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 174 participants |
| Start Date | 2019-10-01 |
| Est. Completion | 2024-07-26 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04132830
The ClinicalTrials.gov registry entry for NCT04132830 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 174 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which In Utero HIV Exposure is the first listed.
NCT04132830 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04132830 about?
NCT04132830 is a clinical study titled "HIV Exposure in Utero and Metabolic Disease Risk in HIV-Negative Young Adults". Globally, over 1 million babies are born to mothers with HIV each year. With the advent of prenatal antiretroviral therapy, up to 98% of these individuals may be HIV-exposed uninfected (HEU). A growing literature suggests that in utero HIV exposure - even in the absence of subsequent infection - may...
What is the current status of trial NCT04132830?
This trial is currently completed. The enrollment target is 174 participants. The study started on 2019-10-01. Estimated completion is 2024-07-26.
What interventions are being tested in trial NCT04132830?
The interventions under investigation include: In Utero HIV Exposure (OTHER), No In Utero HIV Exposure (OTHER).
Who is sponsoring clinical trial NCT04132830?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.